Octapharma Making IGIV Widely Available at 340B Pricing

by Admin | June 28, 2012 12:19 pm

June 28, 2012—Human protein products manufacturer Octapharma USA has announced an initiative to make its octagam 5% immune globulin intravenous (IGIV) therapy for primary immune deficiency widely available to 340B covered entities.

“Octapharma is committed to providing therapies to treat life-threatening conditions to all patients, including those who are treated in facilities that have historically faced challenges accessing IGIV,” Octapharma USA President Flemming Nielsen said in a June 26 prepared statement. 

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1].    Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

 

Endnotes:
  1. Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
  2. Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2012/06/octapharma-making-igiv-widely-available-at-340b-pricing/

Copyright ©2026 340binformed.org unless otherwise noted.